Phlorizin

Phlorizin

SCHEMBL22022720

O=C(CCc1ccc(O)cc1)c1c(O)cc(O)cc1O[C@@H]1OC(CO)[C@@H](O)C(O)C1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SLC5A1 P13866 14/20 1.00
SLC5A2 P31639 5/20 1.00
SLC28A3 Q9HAS3 3/20 1.00
HPGD P15428 2/20 1.00
HSD17B10 Q99714 2/20 1.00
KDM4E B2RXH2 1/20 1.00
CYP3A4 P08684 1/20 1.00
MAPT P10636 1/20 1.00
THRB P10828 1/20 1.00
CYP2C9 P11712 1/20 1.00
CYP2C19 P33261 1/20 1.00
SLC28A2 O43868 1/20 1.00
EPHX2 P34913 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phlorizin SCHEMBL18058585 1.00 SLC5A1 (1.00) SLC5A1SLC5A2SLC28A3HPGDHSD17B10
Phlorizin SCHEMBL16421567 1.00 SLC5A1 (1.00) SLC5A1SLC5A2SLC28A3HPGDHSD17B10
Phlorizin SCHEMBL113699 1.00 SLC5A1 (1.00) SLC5A1SLC5A2SLC28A3HPGDHSD17B10
Phlorizin SCHEMBL2826870 1.00 SLC5A1 (1.00) SLC5A1SLC5A2SLC28A3HPGDHSD17B10
Phlorizin SCHEMBL17290 1.00 SLC5A1 (1.00) SLC5A1SLC5A2SLC28A3HPGDHSD17B10
Phlorizin SCHEMBL23802544 1.00 SLC5A1 (1.00) SLC5A1SLC5A2SLC28A3HPGDHSD17B10
Phlorizin SCHEMBL7647026 0.99 SLC5A1 (0.98) SLC5A1SLC5A2SLC28A3HPGDHSD17B10
Phlorizin SCHEMBL28823647 0.99 SLC5A1 (0.98) SLC5A1SLC5A2SLC28A3HPGDHSD17B10
Phlorizin SCHEMBL18523288 0.99 SLC5A1 (0.98) SLC5A1SLC5A2SLC28A3HPGDHSD17B10
Phlorizin SCHEMBL8861774 0.99 SLC5A1 (0.98) SLC5A1SLC5A2SLC28A3HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216411-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS CLASS I MUTATIONS ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO 2024-07-04 US disclosed
US-20230049572-A1 FORMULATION, COMPOSITION OR FOODSTUFF ADDITIVES FOR THE MODIFICATION OF GLYCEMIC RESPONSE METHODS OF MANUFACTURING AND USING THE SAME HOOW FOODS PTE. LTD. (SG) 2023-02-16 US disclosed
US-20220000959-A1 APPLE PEEL POLYPHENOL EXTRACT FOR THE PREVENTION AND THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE LEAHY ORCHARDS INC. (CA) 2022-01-06 US disclosed
US-20210220379-A1 PERITONEAL SODIUM-GLUCOSE TRANSPORTER (SGLT) INHIBITORS FOR IMPROVEMENT OF PERITONEAL DIALYSIS MOR RESEARCH APPLICATIONS LTD. (IL) 2021-07-22 US disclosed
WO-2020097723-A1 APPLE PEEL POLYPHENOL EXTRACT FOR THE PREVENTION AND THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE LEAHY ORCHARDS INC. (CA) 2020-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210220379-A1 PERITONEAL SODIUM-GLUCOSE TRANSPORTER (SGLT) INHIBITORS FOR IMPROVEMENT OF PERITONEAL DIALYSIS SLC5A1, SLC2A4, SLC2A1 SLC5A1 1/4885SLC5A2 4/4885SLC28A3 27/4885
US-20230049572-A1 FORMULATION, COMPOSITION OR FOODSTUFF ADDITIVES FOR THE MODIFICATION OF GLYCEMIC RESPONSE METHODS OF MANUFACTURING AND USING THE SAME G6PC1, MGAM, GID4 SLC5A1 36/4885SLC5A2 38/4885SLC28A3 4461/4885
US-20240216411-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS CLASS I MUTATIONS SLC5A1, CFTR, SLC5A2 SLC5A1 1/4885SLC5A2 3/4885SLC28A3 68/4885
US-20220000959-A1 APPLE PEEL POLYPHENOL EXTRACT FOR THE PREVENTION AND THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE GOT2, FABP2, LIPC SLC5A1 1311/4885SLC5A2 796/4885SLC28A3 634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.